- Diana Romero
The Molecular Diagnostics Unit (MDU) is entrusted to provide our National Health System’s hospitals with a wide range of sensitive, specific, reliable and updated assays. By using golden standard molecular techniques, we routinely identify alterations in the sequence or expression of key genes that are involved in cancer and that could in turn be used in the diagnosis and/or prognosis of patients, the detection of minimal residual disease in patients showing clinical remission, or for monitoring response to therapy. Our Unit also provides support to CNIO’s Clinical Research Units and Research Groups by developing and implementing novel solutions for their research needs. Involved in the global efforts to standardise and improve molecular diagnostics testing in cancer, we work in partnership with international and national consortia dedicated to these objectives. Finally, our Unit remains fully committed to promoting laboratory training and mentoring for students, technicians and medical residents.
- (2019). Tumor-associated macrophage-secreted 14-3-3? signals via AXL to promote pancreatic cancer chemoresistance. Oncogene 38, 5469-5485. CNIO Publication.